Welcome to our dedicated page for Stevanato Group S P A SEC filings (Ticker: STVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the performance of a company that manufactures both ready-to-fill glass syringes and the robots that inspect them can feel overwhelming. Stevanato Group’s filings often span hundreds of pages that mix drug-containment revenue, engineering backlog, and rigorous FDA quality metrics. If you have ever asked, “How do I read the Stevanato Group annual report 10-K simplified?” or “Where are Stevanato Group insider trading Form 4 transactions listed?”—you are in the right place.
Stock Titan’s platform delivers AI-powered summaries that turn complex disclosures into plain English. You’ll see real-time alerts the moment a Stevanato Group quarterly earnings report 10-Q filing or an 8-K material event hits EDGAR. Our engine highlights segment margins from Pharmaceutical Systems, cap-ex on new glass-forming lines, and even flags Stevanato Group Form 4 insider transactions real-time so you never miss an executive stock purchase or sale. Questions like “understanding Stevanato Group SEC documents with AI” and “Stevanato Group earnings report filing analysis” are answered automatically—no manual page-scrolling required.
Whether you’re monitoring Stevanato Group executive stock transactions Form 4, dissecting the proxy statement executive compensation, or need the 8-K material events explained in context of new sterile factory builds, our coverage makes the data practical. Download the full PDF, skim the AI summary, or jump straight to tables on segment revenue—all from one screen. Stop hunting across filings; get Stevanato Group SEC filings explained simply and make faster, better-informed decisions.
Stevanato Group S.p.A. reported unaudited Q3 and nine‑month 2025 results showing higher sales and profitability. Q3 revenue was €303.2 million (up from €277.9 million), with operating profit of €52.7 million and net profit of €36.1 million; basic EPS was €0.13 (vs €0.11). Nine‑month revenue reached €839.8 million (vs €773.4 million), operating profit €128.7 million, and net profit €92.3 million.
Growth was led by the Biopharmaceutical and Diagnostic Solutions segment (Q3 €266.7 million), including a step‑up in high‑value solutions (€147.9 million vs €100.4 million). The Engineering segment posted €36.4 million. Cash from operations strengthened to €192.0 million year‑to‑date, while capex of €187.7 million supported the ramp‑up of the Fishers (U.S.) and Latina (Italy) sites. The company entered a rent‑to‑buy agreement for its Zhangjiagang, China facility and reported cash of €113.3 million at period end.
The effective tax rate improved to 25.2% for the nine months, reflecting Italy’s one‑year “IRES premiale” benefit. Net foreign exchange effects were a loss of €14.0 million year‑to‑date. One customer represented 12.6% of nine‑month revenue.
Artisan Partners reported beneficial ownership of 2,733,782 ordinary shares of Stevanato Group S.p.A., representing 5.5% of the class based on 49,604,649 shares outstanding as of 06/12/2025. The filing shows shared voting power of 2,316,046 and shared dispositive power over 2,733,782 shares, with no sole voting or dispositive power reported. The shares were acquired for discretionary clients of Artisan Partners Limited Partnership and the filers certify the holdings were acquired in the ordinary course of business and not for the purpose of changing or influencing control.
FAQ
What is the current stock price of Stevanato Group S P A (STVN)?
What is the market cap of Stevanato Group S P A (STVN)?
